Ebola actually gets worse, news for Merck cancer treatment gets better (Morning Read)

Bad news about ebola. Good news for Merck and its skin cancer treatment. And the wellness industry continues to crumble – but who lets facts get in the way? Read today’s MedCity Morning Read.


Ebola may be contractible through sexual intercourse. That changes the game a bit.

Big news for Merck’s skin-cancer treatment Keytruda: it topped Bristol-Myer Squibb’s Yervoy and applied for FDA approval.


No good news for Teva: a generic version of its MS drug gets an FDA OK and it doesn’t seem people are fan of the concept of a Mylan acquisition.

Weekend test results suggest “CAR-T therapies might have a role as a treatment in the much larger solid tumor cancer market.”

Australian VCs have built a $200 million fund to keep Australian companies from heading overseas.

Pfizer and Provectus Biopharmaceuticals expand the patent for PV-10 to be used with systemic immunotherapy agents to treat cancer

Biggest acquirers in the last five years:

  1. Boston Scientific Corporation
  2. Shire
  3. Pfizer, Takeda Pharmaceutical, Bristol-Myers Squibb, Teleflex, C.R. Bard and Covidien

Liquid biopsy gets the New York Times treatment.


Hearings this week will discuss whether the FDA should regulate homeopathic medicine

Is the wellness industry crumbling before our eyes?

It appears that neither the President nor Congress seem to have access to the internet, because for all its support and corporate popularity (most large companies now require employees to participate or else forfeit hundreds of dollars), wellness is generally agreed to be the worst idea in the ACA. Wellness damages employee morale and increases the cost of insurance.

Sepsis deaths will not be change “without radical rethink of research strategy.”

Total cost of the Denver VA hospital? $2 billion+

Are ADHD drugs the pills of choice for workers seeking to be more productive?


Some of the best final HIMSS analysis:

  • The Health Care Blog’s HIMSS Wrap Up: “With all the talk of interoperability, there was considerable chatter about FHIR and its potential as the next big technology to facilitate data exchange.”
  • HIMSS15: The Patient Takes Center Stage: “Perhaps this kind of interaction points to why SXSW is such an interesting venue for conversation about healthcare experiences—you can’t help but notice the individuality of humans walking around Austin striving to be different, be noticed, be heard, be themselves, and be accepted for it. This is precisely what patients want…”

Outright mockery of CIOs who think they own patient engagement.

Moore’s Law turned 50 today, nerds, and Intel did lots of nerdy stuff around it


Take a look at the innovation waiver that could make Obamacare even more confusing than it already it is.

WHO reform because of Ebola? We’ll believe it when we see it.


This is a survey I know you’re going to want to take. Harvard Business Review asks: How does late-night e-mailing affect you?

After you answer the questions below, you’ll see how you compare to other respondents and you’ll receive advice gleaned from articles we’ve published on email overload, sleep, work/life balance, and other related topics.

The results are so fascinating you’ll want to copy and paste the results (boo to HBR for not doing one of those Facebook-embedable results like a Buzzfeed quiz).

For the record, I found this at 1:18 a.m. and dropped a few e-mails later that night/morning.

The Morning Read provides a 24-hour wrap up of everything else healthcare’s innovators need to know about the business of medicine (and beyond). The author of The Read published it but all full-time MedCity News journalists contribute to its content.